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Abstract 
In this paper we report the crystal growth of four cocrystals of furosemide (4-chloro-2-[(2-
furanylmethyl)amino]-5-sulfamoylbenzoic acid), a loop diuretic drug used for the treatment of 
hypertension and oedemas, prepared with p-aminobenzoic acid, nicotinamide and 
isonicotinamide as coformers. We present four new crystal structures and elucidate the 
intermolecular interactions present in the cocrystals. The structures display interesting 
supramolecular chemistry: a number of different synthons, as well as short strong hydrogen 
bonds with partial proton transfer and indications of proton disorder. Using powder X-ray 
diffraction, solid state NMR and thermal analysis, we provide evidence for the preparation of 
bulk samples of two compositions, namely, the 1:1 cocrystal of furosemide and p-aminobenzoic 
acid and 2:1 cocrystal of furosemide and isonicotinamide, highlighting the general necessity of 
such multi-technique approaches to characterisation of organic solids (including cocrystals and 
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solvates) prepared by grinding methods. Finally, we correlate the structural features reported for 
the first time in this work with the previously published pharmacologically relevant properties 
(solubility and intrinsic dissolution rate) of the furosemide cocrystals. 
1. Introduction 
Aqueous solubility and intestinal permeability of the active pharmaceutical ingredient (API), 
together with the dissolution of the formulated product, are three major factors which determine 
drug absorption and ultimately its efficacy. The Biopharmaceutics Classification System (BCS) 
classifies drug substances into four groups according to their solubility and permeability 
properties: class I (high permeability, high solubility), class II (high permeability, low solubility), 
class III (low permeability, high solubility) and class IV (low permeability, low solubility).1 
Overcoming the low permeability problem is primarily a task for formulation scientists, and 
much work has been targeting the development of permeability-enhancing excipients.2 
Improving the solubility of solid drug substances, on the other hand, is an important and topical 
research goal in the area of organic solid state chemistry, and cocrystallisation is emerging as an 
increasingly prominent approach to achieving this goal.  
Cocrystals can be broadly described as crystalline multi-component adducts comprising neutral 
molecules held together by noncovalent interactions. In pharmaceutical cocrystals, the key 
components are API molecules and appropriate benign coformer molecules, typically substances 
on the GRAS list.3 Design and preparation of cocrystals are widely thought of as based on the 
supramolecular synthon approach4, i. e. on the existence of complementary functional groups in 
the API and coformer molecules. With compatible functional groups, noncovalent interactions 
(primarily hydrogen bonding) are likely to arise and lead to cocrystal formation. 
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Furosemide (FS, Figure 1), 4-chloro-2-[(2-furanylmethyl)amino]-5-sulfamoylbenzoic acid, is a 
loop diuretic drug used for the treatment of hypertension and oedemas arising from cardiac, renal 
and hepatic failure.5 It is a class IV drug according to the BCS, suffering from both low 
permeability and low solubility.6 The furosemide permeability and delivery-related issues have 
been addressed by a number of approaches, the most recent ones being emulsification and the 
use of mesoporous materials as carriers.7-9 Cocrystallisation is amongst methods with the 
potential to provide a significant improvement in solubility, according to the recent findings of 
Goud et al.10 The formation of cocrystals between furosemide and eight different coformers 
(caffeine, urea, p-aminobenzoic acid, acetamide, nicotinamide, isonicotinamide, adenine and 
cytosine) was reported and the improved solubility and dissolution of these materials relative to 
pure furosemide was demonstrated. However, only two of the compositions (caffeine and 
cytosine cocrystals) were obtained as single crystals which are needed for accurate structure 
determination by X-ray diffraction, for elucidation of the hydrogen bonding interactions leading 
to cocrystal formation and for structure-property correlations; in the remaining six cases, the 
cocrystal structures remained unknown.  
A further problem arising from the absence of accurate crystal structures can be a limited 
ability to establish with a high degree of certainty the phase purity and identity of the bulk 
material characterised. Ueto et al.11 have determined the crystal structures of four forms of the 
furosemide-nicotinamide cocrystals using laboratory powder X-ray diffraction. In this work, a 
large number of restraints were used in the Rietveld refinements of the non-hydrogen atoms 
(bond length and angle restraints, planar restraints on the phenyl, furan and pyridine rings, on 
carboxyl groups and on amide groups); all hydrogen atoms were placed geometrically and fixed 
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during the refinements. This again resulted in a lack of accurate and precise structural 
information needed to establish the key intermolecular interactions. 
In this paper we report successful crystal growth of four furosemide cocrystals, prepared with 
p-aminobenzoic acid, nicotinamide and isonicotinamide as coformers. We present four new 
crystal structures and elucidate the intermolecular interactions present in these cocrystals. Using 
powder X-ray diffraction, solid state NMR and thermal analysis, we provide evidence for the 
preparation of bulk samples of two compositions, namely, the 1:1 cocrystals of furosemide and 
p-aminobenzoic acid and 2:1 cocrystals of furosemide and isonicotinamide, highlighting the 
general necessity of such multi-technique approaches to characterisation of organic solids 
(including cocrystals and solvates) prepared by grinding methods. Finally, we address the 
implications of the structural features found in this work for the previously published 
pharmacologically relevant properties of the furosemide cocrystals. 
2. Experimental 
2.1. Materials: Acetone was obtained from Fischer Chemicals (99.98 %). All other chemicals 
were obtained from Sigma Aldrich: furosemide (≥ 98 %), nicotinamide (≥ 99.5 %), 
isonicotinamide (99 %), p-aminobenzoic acid (99 %) and acetonitrile (99.5 %). 
2.2. Cocrystallisation: Cocrystallisation of furosemide and p-aminobenzoic acid, 
nicotinamide and isonicotinamide coformers was attempted by solvent evaporation 
method from a variety of solvents and by neat and liquid-assisted grinding. We describe 
below only the preparations which gave the desired pure products.  
FS – NCT (1:1): Equimolar quantities of FS (99 mg, 0.300 mmol) and NCT (12.2 mg, 
0.300 mmol) were weighed out, combined and dissolved in 1.5 ml of ethanol. The solution 
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was then refluxed for 10 minutes and left in a vial with pierced lid for the solvent to 
slowly evaporate at room temperature. Colourless elongated plate-shaped crystals started 
appearing after about 10 days. 
FS – INA (1:1): Equimolar quantities of FS (33 mg, 0.100 mmol) and INA (12.2 mg, 
0.100 mmol) were weighed out and dissolved separately in 1.0 ml of acetone and water, 
respectively. The solutions were then combined and left in a vial with pierced lid for the 
solvent to slowly evaporate at room temperature. Colourless elongated plate-shaped 
crystals started appearing after about 9 days. 
FS – INA (2:1): Single crystals of FS-INA 2:1 grew in the same cocrystallisation batch 
described above, from equimolar quantities of FS (33 mg, 0.100 mmol) and INA (12.2 
mg, 0.100 mmol). They were also elongated colourless plates, and could not be visually 
distinguished from the 1:1 cocrystals. FS – INA 2:1 bulk cocrystal material was prepared 
by weighing out stoichiometric quantities of FS (264 mg, 0.800 mmol) and INA (48.8 mg, 
0.400 mmol) and grinding them in a mortar and pestle for 30 minutes after the addition of 
1 mL of acetone. A further 1 mL of acetone was added after 5 minutes of grinding and an 
additional 0.5 mL after 10 and 20 minutes. 
FS – PABA (1:1): Equimolar quantities of FS (99 mg, 0.300 mmol) and PABA (41.1 mg, 
0.300 mmol) were weighed out, combined and dissolved in 1.5 ml of ethanol. The solution 
was then refluxed for 10 minutes and left in a vial with pierced lid for the solvent to 
slowly evaporate at room temperature. Colourless elongated plate-shaped crystals started 
appearing after about 1 day. The same cocrystal was obtained from an identical synthesis 
using 1.5 mL of methanol as solvent, with colourless elongated plate-shaped crystals 
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appearing after about 1 day. FS – PABA bulk cocrystal material was prepared by weighing 
out stoichiometric quantities of FS (264 mg, 0.800 mmol) and PABA (5109.6 mg, 0.800 
mmol) and grinding them in a mortar and pestle for 30 minutes after the addition of 1 mL 
of acetone. A further 1 mL of acetone was added after 5 minutes of grinding and an 
additional 0.5 mL after 10 and 20 minutes.  
2.3. Single crystal X-ray diffraction: Single crystal X-ray diffraction data on FS-NCT, FS-
INA and FS-INA 2:1 were collected on a Bruker SMART 6000 diffractometer with a 
CCD area detector, using graphite monochromated MoKα radiation. In each data 
collection, a full sphere of data was collected by a series of ω scans, using a frame width 
of 0.3 ° in ω and exposure times between 20 and 40 seconds per frame, depending on the 
crystal. The raw data were collected using the SMART software and integrated using the 
SAINT suite of programs; 12 this included performing an empirical absorption correction 
in SADABS and reduction in XPREP. Single crystal X-ray diffraction data on FS-PABA 
cocrystals were collected on beamline I19 at Diamond Light Source, using a wavelength 
of 0.6889 Å and a standard hemisphere data collection (sample to detector distance 60 
mm, 2θ detector position 30o). Data were collected as 1sec/ o exposures, with 0.5mm Al 
beam attenuation. Structure solution was carried out using SIR92 and structure refinement 
on F2 was carried out using CRYSTALS.13, 14 Positional and anisotropic atomic 
displacement parameters (adps) were refined for all non-hydrogen atoms. A mixed 
hydrogen atom treatment was used: most hydrogen atoms were placed geometrically 
treated using a riding model, except for those involved in hydrogen bonding, whose 
fractional coordinates and isotropic atomic displacement parameters were freely refined. 
All crystallographic details are given in Table 1. 
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2.4. Powder X-ray diffraction: Powder X-ray diffraction data were collected on a Bruker D8 
ADVANCE diffractometer (CuKα1,2 radiation) and a LynxEye detector. Patterns were 
recorded in ranges between 2 and 60° using a step size of 0.014 °. Data analysis was 
carried out using Topas-Academic software.15  
2.5. Solid state NMR: Solid state C13 NMR spectra were recorded on a Varian VNMRS 400 
spectrometer. CP-MAS measurements were carried out using a 6.8 kHz spinning rate and 
a contact time of 1.0 ms. Spectra were referenced to neat tetramethylsilane. 
2.6. Thermal analysis: DSC measurements were carried out using TA DSC Q1000 instrument 
equipped with a nitrogen purge gas. 4-5 mg of sample was typically used for analysis. The 
heating rate was 10o/min. 
Table 1: Crystallographic details for furosemide cocrystals. 
 FS-NCT 1:1 FS-INA 1:1 FS-INA 2:1 FS-PABA 1:1 
Empirical formula C18H17ClN4O6S C18H17ClN4O6S C30H28Cl2N6O11S2 C19H18ClN3O7S 
Molar mass/ g mol-1 452.87 452.87 783.61 467.88 
Temperature/ K 120(2) 120(2) 120(2) 100(2) 
Crystal system Monoclinic Monoclinic Monoclinic Monoclinic 
Space group P21/n P21/n P21/n P21/n 
a/ Å 4.8206(3) 12.8613(15) 5.0178(11) 26.823(5) 
b/ Å 20.6135(14) 5.3305(6) 38.527(8) 4.7607(10) 
c/ Å 19.1406(12) 29.105(3) 17.031(4) 18.427(4) 
β/ deg 93.291(2) 100.016(2) 94.353(3) 122.37(3) 
Volume/ Å3 1898.9(2) 1965.0(4) 3283.0(12) 1987.3(10) 
Z 4 4 4 4 
Reflections collected 19263 15181 24650 17604 
Observed reflections 3336 3448 5701 4461 
Parameters 291 291 471 304 
Goodness of fit 0.93 0.92 0.92 0.99 
R indices (I/σ=2) R = 0.0445 
Rw = 0.0776 
R = 0.0374 
Rw = 0.0731 
R = 0.0978 
Rw = 0.1296 
R = 0.0402 
Rw = 0.0917 
R indices (I/σ=0) R = 0.0747 
Rw = 0.0908 
R = 0.0553 
Rw = 0.0814 
R = 0.1307 
Rw = 0.1370 
R = 0.0592 
Rw = 0.1274 
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3. Results and discussion 
The furosemide molecule possesses a considerable potential for intermolecular interactions with 
coformer molecules via three functional groups which can give rise to hydrogen bonding (the 
sulfonamide group SO2NH2, the carboxyl group COOH and the NH group); these are 
complemented by the coformer molecules chosen (Fig. 1). The variety of hydrogen bonding 
interactions found in the cocrystals characterised in this work are depicted in Fig. 2 and 
discussed for each individual cocrystal separately. 
 
Figure 1: Molecular structure schemes for furosemide (FS), p-aminobenzoic acid (PABA), 
nicotinamide (NCT) and isonicotinamide (INA).  
 
Figure 2: Hydrogen bonding synthons in furosemide cocrystals reported in this work (vide infra). 
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3.1. FS-NCT 1:1 cocrystal 
FS-NCT 1:1 crystal structure: The single crystals obtained from an equimolar mixture of FS 
and NCT in ethanol by slow solvent evaporation correspond to the thermodynamically stable 
polymorph I identified previously by PXRD,11 crystallising in the monoclinic space group P21/n 
with unit cell parameters a = 4.8206(3) Å, b = 20.6135(14) Å, c = 19.1406(12) Å, β = 
93.291(2)o. The asymmetric unit contains one FS molecule and one NCT molecule (Fig. 3). The 
shortest hydrogen bonding interaction occurs between pairs of FS and NCT molecules through 
synthon V (O(20)-H(201)···N(27), dD…A = 2.556(4) Å, Fig. 3 and Fig. 4a), which then loosely 
connect via synthon III (N(24)-H(241) ···O(16)) into zig-zag chains running parallel to the b-
axis, Fig. 4a. Perpendicular to this direction, the chains stack with FS molecules interacting 
through synthon II (N(18)-H(182)···O(17), dD…A = 2.902(5) Å) and NCT molecules stacking via 
synthon VII (N(24)-H(242)···O(16), dD…A = 2.982(5) Å), Fig. 4b. 
 
Table 2: Intermolecular hydrogen bonding distances and angles for the FS-NCT 1:1 cocrystal. 
 Interaction D-H (Å) H···A (Å) D···A (Å) ∠ H-bond (o) 
 V O(20)-H(201)···N(27) 1.08(6) 1.48(6) 2.556(4) 177(6) 
II N(18)-H(182)···O(17) 0.85(4) 2.16(4) 2.902(5) 147(4) 
VII N(24)-H(242)···O(16) 0.82(4) 2.20(4) 2.982(5) 155(3) 
 III N(24)-H(241)···O(16) 0.89(4) 2.23(4) 3.062(5) 155(3) 
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Figure 3: The asymmetric unit in the FS-NCT form I with atom numbering. ADPs are drawn at 
the 50% probability level. Hydrogen atom labels omitted for clarity. 
 
 
Figure 4: Diagram showing the hydrogen bonding present in the FS-NCT form I cocrystal. a) FS-
NCT corrugated chains sustained by synthons V and III, viewed in the (bc) plane; b) hydrogen 
bonding in the perpendicular direction sustained by synthons II and VII. Numbers shown 
represent the D···A distances. 
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The hydrogen bonding parameters derived from our single crystal work shed new insight into 
intermolecular interactions in this cocrystal, which wasn’t attainable from the heavily restrained 
powder diffraction based refinement.11 The most notable and interesting new feature that our 
analysis reveals concerns the interaction in synthon V. This is an O-H···N hydrogen bond with a 
D···A distance of 2.55 Å and a D-H···A angle close to 180o, which classifies it as a short strong 
hydrogen bond (SSHB).16 Typically of SSHBs, the O(20)-H(201)···N(27) interaction has an 
elongated O-H bonded distance of 1.08(6) Å and the isotropic temperature factor of H(201) is 
significantly larger than those of other hydrogen atoms in the structure. The O-H···N hydrogen 
bond with a D···A distance of 2.55 Å falls within the range of very short hydrogen bonds in 
which interesting proton behaviour and dynamics have been observed; examples include the 
temperature-induced reversible proton migration in 4-methylpyridine pentachlorophenol (dO···N = 
2.52 Å at 150 K)17 and in 3,5-pyridinedicarbolylic acid and its deuterated analogue (dO···N = 2.52 
Å  and 2.54 Å at 150 K).18 For this reason, the FS-NCT cocrystals appear to merit further study 
by variable temperature single crystal neutron diffraction if sufficiently large crystals can be 
grown. 
 
3.2. FS-INA 1:1 cocrystal 
FS-INA 1:1 crystal structure: The formation of FS-INA 1:1 cocrystals by grinding was 
reported by Goud et al.;10 however, single crystals were not obtained and no structural 
information was given. We successfully grew single crystals of this composition from an 
equimolar ratio of FS and INA by slow evaporation of a water – acetone solvent mixture. The 
FS-INA 1:1 cocrystals adopt monoclinic space group P21/n, with unit cell parameters a = 
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12.8613(15) Å, b = 5.3305(6) Å, c = 29.105(3) Å, β = 100.016(2)o, and with one FS molecule 
and one INA molecule in the asymmetric unit (Fig. 5).  
 
Figure 5: The asymmetric unit in the FS-INA 1:1 cocrystals with atom numbering. ADPs are 
drawn at the 50% probability level. Hydrogen atom labels omitted for clarity. 
 
FS and INA molecules form pairs via synthon V, O(12)-H(121)···N(28), dD…A = 2.64 Å, (Fig. 
5 and Fig. 6). These pairs link up into centrosymmetric dimers sustained by synthon IV, N(24)-
H(241)···O(22), dD…A = 2.94 Å. Perpendicular to this, the INA dimers interact with FS molecules 
via synthon VIII, forming a moderate NHO hydrogen bond with dD…A = 2.838(4) Å (Fig. 6 and 
Table 3). Finally, FS molecules interact via Cl(1)···O(5) weak halogen bonds, which, with Cl···O 
distances of 3.23 Å, appear to be at the boundary between bonding and non-bonding.19 
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Figure 6: Intermolecular interactions present in the FS-INA 1:1cocrystal. Numbers shown 
represent the D···A distances. 
 
Table 3: Intermolecular hydrogen bonding distances and angles for the FS-INA 1:1 cocrystal. 
Interaction D-H/ Å H···A/ Å D···A/ Å ∠ H-bond/ o 
IV N(24)-H(241)···O(22) 0.86(3) 2.08(3) 2.938(4) 172(3) 
V O(12)-H(121)···N(28) 0.91(5) 1.73(5) 2.638(4) 177(4) 
VIII N(7)-H(72)···O(22) 0.86(3) 2.03(3) 2.838(4) 156(3) 
 
Our attempts to prepare bulk FS-INA 1:1 material by neat and wet grinding resulted in the 
formation of the 2:1 cocrystal (vide infra). For reference we give the calculated PXRD pattern 
obtained using the model derived from the single crystal X-ray structure analysis (Fig. 7). 
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Figure 7: PXRD pattern (CuKα1) for FS-INA 1:1 cocrystal calculated based on the structural 
model presented here. 
3.3. FS-INA 2:1 cocrystal 
FS-INA 2:1 crystal structure: Slow solvent evaporation from equimolar quantities of FS and 
INA from a water – acetone mixture also produced cocrystals in the 2:1 API-to-coformer ratio. 
FS-INA 2:1 crystallises with unit cell parameters a = 5.0178(11) Å, b = 38.527(8) Å, c = 
17.031(4) Å, β = 94.353(3)o, in monoclinic space group P21/n, and with two FS molecules 
(referred to here as FS1 and FS2) and one INA molecule in the asymmetric unit. The most 
striking difference between the two crystallographically unique furosemide molecules is their 
conformation. Disregarding the sulphonamide group, FS1 is essentially planar, with the C(37)-
N(39)-C(40)-C(41) torsion angle of 174o (Fig. 8a-b); the corresponding torsion angle in FS2 is -
83o, leading to a bent molecule (Fig. 8c-d). Similar bent conformations of the furosemide 
molecule are found in triclinic forms I and III of pure furosemide and also in the furosemide-
caffeine cocrystals.10, 20 
Both unique FS molecules in FS-INA 2:1 cocrystals contain disordered fragments: FS1 
displays disorder in the sulphonamide group and FS2 displays disorder in the furan ring. In the 
FS1 molecule, the difference Fourier maps and the subsequent refinement revealed orientational 
disorder of the sulphonamide group, with two components whose occupancies refined to 
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0.51(1):0.49(1), approximately 30o apart. The FS2 molecule was best modelled with a 
0.67(1):0.33(1) positional disorder of the furan ring. The true nature of the disorder of 
furosemide molecules in FS-INA 2:1 cocrystals, however, can only be probed by systematic 
variable temperature diffraction or solid state NMR study, which is outside the scope of this 
work. 
 
Table 4: Intermolecular hydrogen bonding distances and angles for the FS-INA 2:1 cocrystal. 
Interaction D-H/ Å H···A/ Å D···A/ Å ∠ H-bond/ o 
VI O(14)-H(14)···O(46) 0.74(6) 1.88(7) 2.62(1) 176(7) 
VI N(48)-H(481)···O(15) 0.98(7) 1.88(7) 2.82(1) 160(6) 
V O(35)-H(35)···N(52) 0.93(7) 1.63(7) 2.55(1) 167(6) 
III N(48)-H(482)···O(20) 0.80(6) 2.27(7) 3.05(1) 166(5) 
 
 
Figure 8: Two unique furosemide molecules in FS-INA 2:1 cocrystals. (a)-(b): two views of the 
FS1 molecule; (c)-(d): two views of the FS2 molecule.  In each molecule, only one of the 
disordered fragments is shown for clarity. ADPs are drawn at the 50% probability level. 
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The INA molecule interacts with a FS1 molecule via synthon VI, with O(14)-H(14)···O(46) 
and N(48)-H(481)···O(15) donor-acceptor distances of 2.62(1) and 2.82(1) Å, respectively. This 
INA molecule also interacts strongly with a FS2 molecule through synthon V forming a short 
hydrogen bond, O(35)-H(35)···N(52) with dO···N = 2.55(1) Å, and weakly with another FS1 
molecule through synthon III, N(48)-H(482)···O(20) with dO···N = 3.05(1) Å (Fig. 9). FS2 
molecules also interact with like molecules through pairs of sulphonamide groups. These 
interactions are difficult to describe precisely due to the positional disorder present in these 
groups; there are two possible interactions arising from the two disordered components, which 
are presumably similarly favourable. Hydrogen bonding geometries are summarised in Table 4. 
 
Figure 9: Intermolecular interactions present in the FS-INA 2:1 cocrystal. Numbers shown 
represent the D···A distances. 
FS-INA 2:1 bulk material characterisation: The grinding procedure described in the 
Experimental Section yielded a cream coloured powder. The structural model obtained from the 
single crystal X-ray analysis was used to perform Rietveld fitting of the observed PXRD pattern, 
which confirmed the product obtained is nearly a single crystalline phase; a small amount of an 
impurity is suggested by the weak peak at about 15.3o 2θ, which is not predicted by the FS-INA 
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2:1 crystal structure (Fig. 10). The identity of this impurity is unknown; however, it is not any of 
the starting materials or the 1:1 FS-INA cocrystal. Given the preparation conditions, the most 
likely explanation is the formation of a very small amount of an acetone solvate. The fact that a 
single melting endotherm is observed in the DSC trace of this sample (vide infra) confirms that it 
is an essentially single phase product, with any impurity at a very minor level. 
 
 
Figure 10: Rietveld fit for the FS-INA 2:1 cocrystal obtained by grinding. Rwp = 4.744%, a = 
5.112(1) Å, b = 38.756(7) Å, c = 17.052(4) Å, β = 94.27(3) o, V = 3369(1) Å3. 
 
Solid state 13C NMR was performed on FS, INA, on the lightly mixed physical mixture 
of the two starting components and on the cocrystal product (Fig. 11a). The latter shows a 
number of chemical shift changes in the spectrum relative to pure FS and INA. In contrast, the 
spectrum of a 1:1 physical mixture of the reagents corresponds to the sum of the individual 
spectra of FS and PABA.  
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Figure 11: (a) Solid state 13C NMR data showing an overlay of the FS, INA and the FS-INA 2:1 
cocrystal spectra. (b) DSC (endothermic up) of FS-INA 2:1 cocrystal. 
 
A DSC trace recorded on the FS-INA 2:1 cocrystal produced by grinding is depicted in Fig. 
11b. This shows a single endotherm, corresponding to the melting temperature of 204.3oC for the 
cocrystal. This melting point is between the measured melting points of the API and the 
coformer (220.7oC and 158.0oC, respectively), in agreement with a trend generally observed in 
cocrystals.21 
The appearance of the PXRD pattern shown in Fig. 10 suggests that an amorphous component 
exists in the bulk product, which is not surprising in a product prepared by grinding of soft 
organic materials. This, however, necessitates additional characterisation by complementary 
techniques to rule out the possibility that the amorphous component represents an unwanted 
impurity. In this case, the NMR spectra and DSC curve together confirm that any amorphous 
component in the sample is the target cocrystal itself.  
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3.4. FS-PABA 1:1 cocrystal 
FS-PABA 1:1 crystal structure: FS-PABA 1:1 cocrystals adopt monoclinic space group 
P21/n with unit cell parameters a = 26.823(5) Å, b = 4.7607(10) Å, c = 18.427(4) Å, β = 
122.37(3)o , and with one FS molecule and one PABA molecule in the asymmetric unit (Fig. 11).  
 
Figure 11: The asymmetric unit in the FS-PABA 1:1 cocrystals with atom numbering. ADPs are 
drawn at the 50% probability level. Hydrogen atom labels omitted for clarity. 
 
Both types of molecules form dimers sustained by synthon I. Pairs of FS molecules form 
dimers through O(14)-H(141)···O(15) hydrogen bonding (dO···O = 2.613(4) Å), while PABA 
molecules pair via O(24)-H(241)···O(22) interactions (dO···O = 2.618(5) Å), Fig. 12a. Despite the 
same synthon and an essentially identical donor – acceptor distance in the two types of dimers, 
the hydrogen bonding in them differs significantly. In the FS dimers, the key hydrogen atom, 
H(141), is located on the O(4) donor (dO(4)-H(141) = 0.97(4) Å). The asymmetric nature of this 
hydrogen bond is manifested in the C-O atom distances in this COOH functional group; C(7)-
O(3) and C(7)-O(4) bond length values of 1.237(3) Å and 1.319(3) Å clearly reflect the double 
and single character of these bonds, respectively.18 By contrast, partial proton transfer occurs in 
the PABA dimer hydrogen bond. The O(24)-H(241) distance (1.21(9) Å) and a large isotropic 
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displacement parameter for H(241) suggest possible proton disorder in this hydrogen bonded 
dimer. In this case the distances dC(23)-O(22) = 1.278(3) Å and dC(23)-O(24) = 1.280(3) Å belong to 
the region between the C-O bond length distribution maxima representing single and double 
bonds;18 this situation is consistent with a significant degree of proton transfer in the OHO 
hydrogen bond in the PABA dimer. PABA dimers are arranged in a herringbone motif (Fig. 
12b), while the two types of dimers interact weakly via synthon III, N(29)-H(292)···O(20), 
forming an extended hydrogen bonding network. The O-H oxygen atom in PABA is also 
involved in a halogen bond with the chlorine atom of a FS molecule, C(2)-Cl(1)···O(24), with 
dCl···O = 3.054(4) Å. 
 
Figure 12: Intermolecular interactions in the FS-PABA cocrystal. a) FS and PABA dimers 
viewed in the (bc) plane; b) herringbone motif formed by PABA dimers, with interspersed FS 
dimers. Numbers shown represent the D···A distances. 
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Table 5: Intermolecular hydrogen bonding distances and angles for the FS-PABA cocrystal. 
Interaction D-H/ Å H···A/ Å D···A/ Å ∠ H-bond/ o 
I O(14)-H(141)···O(15) 0.97(4) 1.64(4) 2.613(4) 179(4) 
I O(24)-H(241)···O(22) 1.21(9) 1.45(9) 2.618(5) 160(9) 
III N(29)-H(292)···O(20) 0.86(4) 2.20(4) 3.054(4) 168(3) 
 
 
FS-PABA bulk material characterisation: The liquid-assisted grinding procedure yielded an 
off-white (pale pink) powder. The structural model obtained from the single crystal X-ray 
analysis was used to perform Rietveld fitting of the observed PXRD pattern, which confirmed 
the product obtained is single phase (Fig. 13).  
 
Figure 13: Rietveld fit for the FS-PABA cocrystal obtained by liquid-assisted grinding. Rwp = 
4.955%, a = 27.004(2) Å, b = 4.8085(3) Å, c = 18.587(1) Å, β = 122.506(5) o, V = 2035.4(3) Å3. 
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Figure 14: (a) Solid state 13C NMR data showing an overlay of the FS, PABA and the FS-PABA 
cocrystal spectra. (b) DSC (endothermic up) of FS-PABA. 
 
Solid state 13C NMR was performed on the cocrystal, both individual components and on the 
physical mixture. Comparison reveals changes in the chemical shift of a number of peaks in the 
cocrystal spectrum with respect to pure FS and PABA. Finally, the DSC (Fig. 14b) confirms the 
obtained product to be a pure, single phase FS-PABA cocrystal through the presence of only one 
melting endotherm. The melting temperature for the cocrystal, 201.0 oC, is between the melting 
points of the API and the coformer (220.7 oC and 189.4 oC, respectively). These complementary 
techniques again demonstrate that a small amorphous component present in the product is not an 
impurity, but the target cocrystal. 
 
4. Structure-property relationships 
Goud et al.10 have reported two sets of pharmacologically relevant properties, namely 
solubility and intrinsic dissolution rate in 10% ethanol – water,  for pure FS and a number of its 
cocrystal compositions. The crystal structures of only two cocrystals (furosemide with caffeine, 
FS-CAFF and with cytosine, FS-CYT) were known at the time, which limited the scope for 
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rationalisation of the properties observed. Goud et al.10 attributed a significant (almost 11-fold) 
increase in aqueous solubility of FS-CYT relative to pure furosemide to the fact that this 
composition forms a salt, i.e. the proton from the COOH group of FS is transferred to the basic 
ring N atom of the cytosine molecule.  Secondly, they proposed that the stability of FS-CAFF, 
FS-CYT and FS-ADEN in 10% ethanol – water slurry was a consequence of these being 
congruently dissolving systems, made up of components of similar solubility. However, they 
found FS-PABA cocrystal to be an exception from this trend, being unstable and converting to 
furosemide within 24 hours, and also displaying the smallest improvement in solubility and 
intrinsic dissolution rate relative to pure FS. 
The details of crystal structures and hydrogen bonding presented on our work can shed light on 
these observations. Firstly, none of the four compositions whose structures have been determined 
form salts, and this correlates well with their reported aqueous solubility values being lower than 
that of FS-CYT, although they are still higher than that of pure furosemide. Secondly, the FS-
PABA structure is unique among the furosemide cocrystals in that the intermolecular interactions 
are stronger between pairs of molecules of the same component than between the API and the 
coformer molecules. As shown in Table 5, FS molecules form dimers through O-H···O hydrogen 
bonding with donor-acceptor distances of 2.613(4) Å, and these dimers then connect to PABA 
molecules via weak N-H···O interactions (donor-acceptor distances of 3.054(4) Å). These 
hydrogen bonding arrangements are very similar to those in pure furosemide, in which FS 
molecules also connect into carboxylic acid dimers (with donor-acceptor distances of 2.635(5) Å 
and 2.672(5) Å), which then weakly interact with other FS molecules via N-H···O interactions  
with donor-acceptor distances of 2.999(5) Å. These similarities in intermolecular interactions in 
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the pure FS and FS-PABA structures can account for an only modest increase of solubility and 
intrinsic dissolution rate of this cocrystal relative to pure API.  
The FS-INA 1:1 cocrystal exhibits superior properties relative to pure furosemide: an increase 
of the solubility in 10 % EtOH-water at 24 h by a factor of 7.2 and an increase in the intrinsic 
dissolution rate in 10 % EtOH-water by a factor of 2.3. The issue with the FS-INA 1:1 cocrystal, 
however, is the low stability; the samples converted to furosemide within 24 hours in a 10 % 
EtOH-water slurry medium. The characterisation of the pharmacologically relevant properties of 
the FS-INA 2:1 cocrystal, reported here for the first time, is beyond the scope of this study. 
However, future work on this system includes measurements of solubility, intrinsic dissolution 
rate and stability using the same methodology employed by Goud et al. 10, in order to acquire 
data for meaningful comparisons. 
 
5. Conclusions 
Several different synthons are present in the forms of FS analysed in this work, as summarised 
in Table 6. However, some general trends can be observed. Synthons II, III and V are formed in 
most of the cocrystals containing the relevant functional groups. Comparisons of bond lengths 
and angles suggest that all occurrences of II and III are of moderate strength; however, in two 
out of three occurrences, synthon V displays very short D···A distances (dN···O = 2.55 Å) between 
the best hydrogen bonding donor and the best hydrogen bonding acceptor in each case, implying 
strong hydrogen bonding interactions.  
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Table 6: Synthons formed in the furosemide cocrystal structures determined in this work. 
 I II III IV V VI VII VIII 
FS form 1 9 9       
FS-NCT 1:1  9 9  9  9  
FS-PABA 1:1 9 9 9      
FS-INA 1:1    9 9   9 
FS-INA 2:1   9  9 9   
 
In contrast, PABA molecules interact by SSHBs through synthon I to form dimers in the FS-
PABA cocrystal. Whilst synthon I can form between FS molecules, it has been shown to be of 
only moderate strength in both pure FS and the FS-PABA cocrystal. The lack of alternative 
interactions for the FS COOH moiety in the FS-PABA cocrystal allows for formation of this 
synthon; however, in the presence of aromatic nitrogen moieties, this synthon does not compete 
favourably with synthon V. Previous studies have found carboxylic acid dimers to be favoured in 
the absence of competing interactions, whilst synthon V is dominant (77% of instances) when 
the relevant functionalities were present.22 This correlates well with the results presented here. 
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TOC Graphic and synopsis 
 
Four new crystal structures of pharmaceutical molecule furosemide with GRAS coformers are 
reported and correlated with the known pharmacologically relevant properties of these materials. 
Furosemide carboxylic acid oxygen donor – coformer aromatic nitrogen acceptor is the dominant 
synthon, leading to the key intermolecular interactions in the cocrystals studied.  
 
 
 
